glp-1 guidelines for weight loss is only severely obese people. The clinical say otherwise. You may qualify for GLP-1 medication if you have a BMI of 30 or higher, OR a BMI of 27 GLP-1 drugs are already famous

In addition to multiple late-breaking clinical trial sessions featuring newly released data on the efficacy of this class of drugs, alone and in combination with other agents, the 2026 Scientific Sessions highlighted the latest findings and guidance on using GLP-1 RA therapies in the Monday, June 8, symposium, GLP-1 Receptor Agonists: Whats New in 2026

PF-06372222 and key residues are shown as sticks

Similarly, as a result of the positive findings from the recent DAPA-CKD trial [90], dapagliflozin is now indicated for the treatment of CKD, and can be initiated if eGFR 25 ml/min/1.73 m 2

Lancet 400 , 18691881 (2022)

Whilst this has not been conclusively demonstrated in humans, caution is advised in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2)

Boom in GLP-1 drugs augurs food industry disruption. Food Business News